<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)" code="C0E-004" /></DRUG2>
<DESCRIPTION>Potentially lethal hyperkalemia, especially with patients having renal insufficiency (addition of the hyperkaliemia producing effects)</DESCRIPTION>
<SEVERITY>Contraindication:</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>423-POTASSIUM.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="POTASSIUM" rxcui="8588">
<ATC code="A12BA" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia producing effects) </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
